|Day Low/High||344.05 / 351.67|
|52 Wk Low/High||249.17 / 370.57|
After Friday's surge another look at BIIB is warranted.
The seemingly terrific rationales for strength in these economically sensitive sectors seem glib until the bigger global economic issues get resolved.
Biogen delivered promising results on a new Alzheimer's disease treatment. And investors rewarded the company accordingly.
Here's what you need to know now for Friday, July 6.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending market topics from the floor of the New York Stock Exchange.
Real Money reveals the crucial component Biogen got right in this trial and what it plans for the drug next.
The company's drug showed promising results versus a placebo in a Phase 2 trial.
The history of trying to cure Alzheimer's is full of mistakes and false promises.
Jim Cramer and our other experts discuss bulls and bears, Biogen, and 4 bargain stocks.
Investors might be finally recognizing the hidden value of the firms' drug research and development.
There are issues in the study that are keeping some buyers cautious and causing selling into the early strength.
Since TheStreet Ratings upgrade on May 1, shares of the biotech giant have recovered strongly.
This biotech's weekly chart is very encouraging.
First Trust NYSE Arca Biotechnology Index Fund and iShares Nasdaq Biotechnology ETF look like two ways to catch the rally in Biogen.
My longer-term price target is now $416.
- The final analysis at 18 months of the 856 patient Phase II clinical study in early Alzheimer's disease demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta accumulated in the brain
The Duchenne Muscular Dystrophy specialist announces early results that show a gene-based treatment for the debilitating disease may be just two years away.
CARLSBAD, Calif., June 5, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.
RESULTS OF THE PHASE II STUDY DEMONSTRATED A STATISTICALLY SIGNIFICANT DIFFERENCE IN AMYLOID BETA IN BRAIN
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Biogen Inc has taken over the #107 spot from Nielsen Holdings PLC , according to ETF Channel. Below is a chart of Biogen Inc versus Nielsen Holdings PLC plotting their respective rank within the S&P 500 over time (BIIB plotted in blue; NLSN plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks from the floor of the New York Stock Exchange.
Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.
Since taking office, President Trump has talked big on reining in drug prices, but the administration's lack of action leaves most expecting a May 11 speech that tastes like a nothing burger.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALOT, AMOV, AMX, ARE, BIIB, BSM, DAN, DO, FUL, GIGM, JD, NGVT, OIS, WLL Downgrades: EQT, IVAC, PTNR, WP Initiations: ICCH Read on to get TheStreet Quant Ratings' detailed report:
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.